$215 Total funding received
Connect

SUMMARY

At Molcure we combine a deep knowledge of Next Generation Sequencing, bioinformatics and molecular biology, into the drug discovery platform, Abtracer. Our Abtracer system is a patent-pending framework combining the phage display technique and NGS-analysis of antibody DNA sequences, using machine learning algorithms. Our company’s aim is to cure the incurable by discovering drugs for diseases with no effective treatment. We do this by providing a groundbreaking new service that enables pharmaceutical companies, who are developing new antibody drugs, to identify antibody candidates 30 times faster, and ten times more likely to identify and unearth the next blockbuster drug. By using Abtracer, our clients can maximize the potential of their current antibody libraries and screening methods.

IMPACT

With longer life spans and an ageing society, there is a growing demand for the treatment of chronic disorders and unmet medical needs. Traditionally, drug development requires huge investments and the time-frame for creating them is long and arduous. Our mission is therefore to maximise drug viability, minimise drop-rate and enable therapeutic biomolecules to enter the market quicker. With biomolecule discovery and an engineering platform, we provide the best drugs for patients in the quickest time. Using the method of phage display for antibody discovery, there is always a risk of losing antibody candidates due to the bacterial amplification bias. Abtracer solves this problem by combining next-generation DNA sequencing with artificial intelligence. One of the great benefits of using Abtracer is being able to find the antibody candidates that conventional methods can never discover in the phage library.

シーバスリーガルニュースレター登録

×

あなたにマッチしたシーバスリーガルの最新情報をいち早くお届けします。登録には下のフォームに必要情報と興味のあるコンテンツを選択ください。 シーバスベンチャーについてもっと知りたい。登録には下のフォームに必要情報と興味のあるコンテンツを選択ください。 Want to know more about Chivas and Manchester United partnership? Simply enter your contact details and preferences to receive our latest news and tailored content directly in your inbox. おすすめのカクテルについてもっと知りたい。登録には下のフォームに必要情報と興味のあるコンテンツを選択ください。

もっとも関心のあるコンテンツ:

興味のあるコンテンツを選択ください。

シーバスリーガルの最新情報を受け取ることに同意する場合は下記チェックボックスを選択ください。

IF YOU’D LIKE TO RECEIVE EXCLUSIVE & TAILOR MADE CONTENT FROM CHIVAS AND MANCHESTER UNITED, PLEASE CONSENT BY TICKING THE BOX BELOW.

取得した個人情報を、シーバスブラザーズ社、またペルノリカールグループ内で法令の範囲内において第三者に開示または提供する目的で利用します。ご本人が自らの個人情報の開示、訂正、サービス等の紹介の停止、または消去などを希望される場合、ご本人であることを確認したうえで、法令の規定に基づき、すみやかに対応します。お問い合わせ窓口につきましては、 otoiawase@pernod-ricard.com までメールにてお願いいたします。詳細は弊社の利用規約をご覧ください。

*By submitting this form, you agree (i) your information may be used by Chivas Brothers Limited and made available through us to other members of the Pernod Ricard Group. At anytime, you can exercise your right of access, rectification, erasure, restriction, portability, objection or with draw your consent at anytime without affecting the lawfulness of processing based on your consent before withdrawal by contacting us at contactus@chivas.com. For more information please read our privacy policy. The Chivas Regal Terms & Conditions apply; and (ii) Manchester United (“MU”) Group using your personal data in accordance with MU’s Privacy Policy (MU use your data to personalise and improve your experience on digital platforms, provide products and services you request from MU, and carry out profiling and market research).